AR077958A1 - ANTOGONIST QUINOXALINONES OF HEPCIDINE - Google Patents

ANTOGONIST QUINOXALINONES OF HEPCIDINE

Info

Publication number
AR077958A1
AR077958A1 ARP100103100A ARP100103100A AR077958A1 AR 077958 A1 AR077958 A1 AR 077958A1 AR P100103100 A ARP100103100 A AR P100103100A AR P100103100 A ARP100103100 A AR P100103100A AR 077958 A1 AR077958 A1 AR 077958A1
Authority
AR
Argentina
Prior art keywords
optionally substituted
anemia
heteroaryl
aryl
alkyl
Prior art date
Application number
ARP100103100A
Other languages
Spanish (es)
Inventor
Vincent Anthony Corden
Peter Otto Geisser
Felix Funk
Stephen Martin Courtney
Stefan Jager
Mark Slack
Christopher John Yarnold
Wilm Buhr
Burckhardt Susanna Dr
Franz Durrenberger
Wei Tsung Yau
Original Assignee
Vifor Int Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vifor Int Ag filed Critical Vifor Int Ag
Publication of AR077958A1 publication Critical patent/AR077958A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Abstract

La presente se refiere a nuevos antagonistas de la hepcidina, composiciones farmacéuticas que los contienen, y su uso como medicamento, particularmente para el tratamiento de desordenes del metabolismo del hierro, en particular enfermedades de deficiencia de hierro y anemia, particularmente anemia asociada con enfermedad inflamatoria cronica y anemia por inflamacion. Reivindicacion 1: Compuestos de la formula general (1) en que R1, R2 y R3 y R4 pueden ser iguales o distintos entre sí y están elegidos del grupo que comprende: hidrogeno, alquilo, arilo, o heteroaril-Sulfonilo, opcionalmente sustituidos, acilo opcionalmente sustituido, alquilo opcionalmente sustituido, alquenilo opcionalmente sustituido, alquinilo opcionalmente sustituido, arilo opcionalmente sustituido, heteroarilo opcionalmente sustituido; o sus sales farmacéuticamente aceptables.This refers to new hepcidin antagonists, pharmaceutical compositions containing them, and their use as a medicine, particularly for the treatment of iron metabolism disorders, in particular iron deficiency diseases and anemia, particularly anemia associated with inflammatory disease. Chronic and inflammation anemia. Claim 1: Compounds of the general formula (1) in which R1, R2 and R3 and R4 may be the same or different from each other and are chosen from the group comprising: hydrogen, alkyl, aryl, or heteroaryl-Sulfonyl, optionally substituted, acyl optionally substituted, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted heteroaryl; or its pharmaceutically acceptable salts.

ARP100103100A 2009-08-27 2010-08-24 ANTOGONIST QUINOXALINONES OF HEPCIDINE AR077958A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09168834 2009-08-27

Publications (1)

Publication Number Publication Date
AR077958A1 true AR077958A1 (en) 2011-10-05

Family

ID=41463016

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103100A AR077958A1 (en) 2009-08-27 2010-08-24 ANTOGONIST QUINOXALINONES OF HEPCIDINE

Country Status (3)

Country Link
AR (1) AR077958A1 (en)
TW (1) TW201113261A (en)
WO (1) WO2011023722A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CO2018004165A2 (en) 2015-10-23 2018-09-20 Vifor Int Ag Ferroportin inhibitors
CN105777622A (en) * 2016-04-13 2016-07-20 山东新华制药股份有限公司 Method for preparing impurities of dabigatran ester intermediate cyclocompound
JOP20180036A1 (en) 2017-04-18 2019-01-30 Vifor Int Ag Novel ferroportin-inhibitor salts

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7166448B1 (en) 1999-05-10 2007-01-23 Children's Medical Center Corproation Ferroportin1 nucleic acids and proteins
DE60231804D1 (en) 2001-05-25 2009-05-14 Inst Nat Sante Rech Med USE OF HEPCIDINE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT OF IRON HOMEOSTASTE DISORDER
US7749713B2 (en) 2002-11-19 2010-07-06 Hasan Kulaksiz Diagnostic method for diseases by screening for hepcidin in human or animal tissues, blood or body fluids and therapeutic uses therefor
US8614204B2 (en) 2003-06-06 2013-12-24 Fibrogen, Inc. Enhanced erythropoiesis and iron metabolism
EP1740557A1 (en) 2004-04-20 2007-01-10 Bayer HealthCare AG Urea derivatives as antagonists of the vanilloid receptor (vr1)
US7723063B2 (en) 2004-04-28 2010-05-25 Intrinsic Lifesciences Methods for measuring levels of bioactive human hepcidin
WO2006094210A2 (en) 2005-03-03 2006-09-08 Sirtris Pharmaceuticals, Inc. Tetrahydroquinoxalinone sirtuin modulators
CA2549477A1 (en) 2005-06-29 2006-12-29 The Regents Of The University Of California Competitive regulation of hepcidin mrna by soluble and cell-associated hemojuvelin
AU2007299629C1 (en) 2006-09-21 2012-05-10 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the HAMP gene
TW201206954A (en) 2007-02-02 2012-02-16 Amgen Inc Hepcidin, hepcidin antagonists and methods of use
CL2008000666A1 (en) 2007-03-07 2008-06-13 Xenon Pharmaceuticals Inc COMPOUNDS DERIVED FROM SUBSTITUTED TRICYCLES, INHIBITORS OF THE DIVALENT-1 METAL TRANSPORTER; AND USE TO TREAT AN ILLNESS ASSOCIATED WITH AN IRON DISORDER.
AR065785A1 (en) 2007-03-19 2009-07-01 Xenon Pharmaceuticals Inc BIARETO AND BIHETEROARILE COMPOUNDS OF UTILITY IN THE TREATMENT OF IRON DISORDERS
WO2008121861A2 (en) 2007-03-28 2008-10-09 Xenon Pharmaceuticals Inc. Pyrazole and pyrrole compounds useful in treating iron disorders
EP2068855A2 (en) 2007-06-05 2009-06-17 Xenon Pharmaceuticals Inc. Aromatic and heteroaromatic compounds useful in treating iron disorders
GR1006896B (en) 2007-08-24 2010-07-20 Ελληνικο Ινστιτουτο Παστερ, A process for producing a peptide hormone.
US8487081B2 (en) 2007-10-02 2013-07-16 INSERM (Institut National de la Santé et de la Recherche Médicale) Antibodies specific for human hepcidin
JO2828B1 (en) 2007-11-02 2014-09-15 ايلي ليلي اند كومباني Anti-Hepcidin Antibodies and Uses Thereof

Also Published As

Publication number Publication date
WO2011023722A1 (en) 2011-03-03
TW201113261A (en) 2011-04-16

Similar Documents

Publication Publication Date Title
UY33921A (en) N-SUBSTITUTED OXAZINOPTERIDINS AND N-REPLACED OXAZINOPTIRIDINONES
AR077999A1 (en) ANTIGONISTS OF PYRIMIDIN AND TRIAZIN-HEPCIDINE
CL2011000589A1 (en) Compounds derived from pyrrolidin-2-carboxamide, p53-mdm2 interaction inhibitors; pharmaceutical composition that includes them; and its use in the preparation of useful medicines for the treatment of cancer.
DOP2011000218A (en) SULFONAMIDE DERIVATIVES
ECSP099750A (en) IMIDAZOQUINOLINAS WITH IMMUNOMODULATING PROPERTIES
UY31885A (en) DERIVED FROM THE 1, 3, 5-TRIAZINA-2, 4-DIAMINAS-6-SUBSTITUTED-N-SUBSTITUTED AND PHARMACEUTICALLY ACCEPTABLE SALTS OF THE SAME, COMPOSITIONS AND APPLICATIONS.
CO6690768A2 (en) Triazine-oxadiazole derivatives, useful as sodium channel inhibitors navi.7
ECSP109903A (en) DERIVATIVES OF PIRAZINONA AND ITS USE IN THE TREATMENT OF PULMONARY DISEASES
NI201200044A (en) IMINOTIADIAZINE DIOXIDE COMPOUNDS AS BACE INHIBODORS, COMPOSITIONS AND THEIR USE
CL2012001911A1 (en) Compounds derived from fumarate; pharmaceutical composition comprising them; and its use in the treatment of an inflammatory or neurodegenerative disease.
UY31046A1 (en) SUBSTITUTED DERIVATIVES OF N- (3,4-DIHIDRO-2H-CROMEN-3-IL) FORMAMIDA AND N- (1, 2,3, 4-TETRAHIDRONAFTALEN-2-IL) FORMAMIDA, SALTS OF THE SAME, COMPOSITIONS THAT CONTAIN THEM , PROCEDURES FOR PREPARATION AND APPLICATIONS
ECSP088747A (en) PIRAZOLES AS INHIBITORS OF THE 11-BETA-HSD1
UY30498A1 (en) NEW CLASS OF BENZIMIDAZOLILO COMPOUNDS, ITS SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND APPLICATIONS
ECSP088975A (en) NEW ANALAGOS DE PIRIDINA
UY31639A1 (en) DERIVATIVES OF SPIROCYCLIC AMIDA OF FORMULA I, PHARMACEUTICALLY ACCEPTABLE SALTS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, PREPARATION PROCESSES AND APPLICATIONS
UY35275A (en) AMINOPIRAZINE DERIVATIVES
DOP2014000036A (en) PIRIDAZINONE COMPOUNDS AND ITS USE AS DAAO INHIBITORS
UY31922A (en) COMPOUNDS
AR070907A1 (en) CRYSTAL FORMS OF NITROCATECOL DERIVATIVE
CO6491060A2 (en) COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITARY DISEASES
UY30856A1 (en) NEW DERIVATIVES OF 2,4 DIANILINOPIRIMIDINAS, ITS PREPARATION, AS MEDICINES, PHARMACEUTICAL COMPOSITIONS AND MAINLY AS IKK INHIBITORS
CO6382089A2 (en) COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASES CAUSED BY A B-AMYLOID AND SINUCLEINOPATIAS
DOP2011000134A (en) WE REACT AS BETA SECRETASA INHIBITORS
AR078278A1 (en) ANTAGONISTS OF TIAZOL AND OXAZOL HEPCIDINE, PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM AND USE OF THE SAME FOR THE TREATMENT OF ANEMIAS AND ILLNESSES ASSOCIATED WITH IRON DEFICIENCIES.
DOP2016000276A (en) 2-AMINO-6-METHYL-4,4a, 5,6-TETRAHYDROPIRANE [3,4-d] [1,3] TIAZIN-8a (8H) -IL-1,3-TIAZOL-4-ILAMIDAS

Legal Events

Date Code Title Description
FB Suspension of granting procedure